Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 4:16 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-214676
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Cost of revenues | 1,227 | 894 |
| Selling and marketing | 14,136 | 10,841 |
| Research and development | 6,738 | 3,095 |
| General and administrative | 7,220 | 4,955 |
| Transaction costs | 2,553 | — |
| Total operating expenses | 31,874 | 19,785 |
| (Loss) income from operations | (9,355) | 2,273 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s R&D?
- Gyre Therapeutics, Inc. (GYRE) reported R&D of $6.74M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s R&D changed year-over-year?
- Gyre Therapeutics, Inc.'s R&D increased by 117.7% year-over-year, from $3.1M to $6.74M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s R&D has grown at a -27.9% compound annual growth rate (CAGR), from $68.89M to $18.62M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Gyre Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude